Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does PEMBROLIZUMAB Cause Therapy partial responder? 1,125 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 1,125 reports of Therapy partial responder have been filed in association with PEMBROLIZUMAB (KEYTRUDA). This represents 1.3% of all adverse event reports for PEMBROLIZUMAB.

1,125
Reports of Therapy partial responder with PEMBROLIZUMAB
1.3%
of all PEMBROLIZUMAB reports
164
Deaths
271
Hospitalizations

How Dangerous Is Therapy partial responder From PEMBROLIZUMAB?

Of the 1,125 reports, 164 (14.6%) resulted in death, 271 (24.1%) required hospitalization, and 32 (2.8%) were considered life-threatening.

Is Therapy partial responder Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for PEMBROLIZUMAB. However, 1,125 reports have been filed with the FAERS database.

What Other Side Effects Does PEMBROLIZUMAB Cause?

Malignant neoplasm progression (10,111) Death (4,744) Diarrhoea (4,251) Fatigue (3,833) Off label use (3,416) Product use in unapproved indication (3,191) Pyrexia (3,155) Rash (2,900) Nausea (2,670) Decreased appetite (2,486)

What Other Drugs Cause Therapy partial responder?

CYCLOPHOSPHAMIDE (1,397) RITUXIMAB (1,219) DEXAMETHASONE (1,199) PREDNISONE (1,176) CARBOPLATIN (1,096) DOXORUBICIN (834) METHOTREXATE (775) VINCRISTINE (707) ETOPOSIDE (670) BEVACIZUMAB (632)

Which PEMBROLIZUMAB Alternatives Have Lower Therapy partial responder Risk?

PEMBROLIZUMAB vs PEMETREXED PEMBROLIZUMAB vs PEMIGATINIB PEMBROLIZUMAB vs PENICILLAMINE PEMBROLIZUMAB vs PENICILLIN PEMBROLIZUMAB vs PENICILLIN G

Related Pages

PEMBROLIZUMAB Full Profile All Therapy partial responder Reports All Drugs Causing Therapy partial responder PEMBROLIZUMAB Demographics